Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands.
about
An allosteric conduit facilitates dynamic multisite substrate recognition by the SCF(Cdc4) ubiquitin ligasePre-Assembly of Near-Infrared Fluorescent Multivalent Molecular Probes for Biological ImagingEngineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer CellsDesign and applications of bispecific heterodimers: molecular imaging and beyondTarget engagement and drug residence time can be observed in living cells with BRET.On the 'micro'-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action.On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targetsCell membranes… and how long drugs may exert beneficial pharmacological activity in vivoTargeting the Two Oncogenic Functional Sites of the HPV E6 Oncoprotein with a High-Affinity Bivalent Ligand.Behaviour of intrinsically disordered proteins in protein-protein complexes with an emphasis on fuzziness.'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models.Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence.Molecular mechanism of allosteric modulation at GPCRs: insight from a binding kinetics study at the human A1 adenosine receptor.Real-time Characterization of Antibody Binding to Receptors on Living Immune Cells.Heterobivalent agents targeting PSMA and integrin-αvβ3.Avidity and positive allosteric modulation/cooperativity act hand in hand to increase the residence time of bivalent receptor ligands.Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time.General principles of binding between cell surface receptors and multi-specific ligands: A computational study.Distinct in vivo target occupancy by bivalent- and induced-fit-like binding drugs.Interferon dimers: IFN-PEG-IFN.Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis.Structure and biophysical characterisation of the human full-length Neurturin-GFRa2 complex - a role for heparan sulfate in signalling.An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.Link between a high for drug binding and a fast clinical action: to be or not to be?
P2860
Q28817978-4394872D-35C4-481B-8645-37D317DD4360Q28829172-D981E25B-0F7C-40CC-BC02-1D1BE834C5CCQ33691823-22CE3C35-9DC3-4F97-AA39-785E8DB084F2Q33732587-F1585DBC-17AB-47E3-B4D5-519D8E927E67Q34503961-A7509983-B798-4DC0-9A06-FDD8981920F6Q38545579-E783AB91-03A9-41C0-AD71-531C9B9EE59AQ38710840-8B3FC4AB-927E-4616-AC28-77351BFF53D8Q38822818-AAE566D2-710A-4C8F-B005-027F7CCF5988Q38870528-5961261E-4E45-49AF-8ADD-8BBA32E15A06Q39361383-A06AD7C6-106C-4CF6-BCCE-8CB084434998Q39786582-788047D2-5985-45D8-BAF0-7D751E7A0FD3Q40971778-CB2B4B5C-0380-46BB-97B9-FDD860839085Q42221343-346F610B-E671-4221-848F-B9EF8BBF4C42Q42290751-C0FE656E-EBC6-4B4E-89A8-AA60A26C4A57Q42751344-7E06ECDE-C9FC-44AE-85A1-EF1D9660B667Q43569767-D863E981-9335-4A56-BFA0-1F21104425B7Q43783930-45A04C92-6666-4D7B-9650-20F473D88EADQ45737672-2DF5B3D1-A061-454F-9B5F-01F53F946A5FQ47714485-BEEE57F2-1493-4E5A-8AD6-D60B48CBE36FQ47939716-24EFBB6D-4EB4-4267-B765-3CDE04E6FC57Q48333797-CFF087C6-33FB-4F26-8393-A6793E5A4FE1Q50134150-3004E729-BBD6-48F3-B3D7-D5894E97AC6DQ51730313-F43810FD-7657-48AC-BED2-C0530D8386CBQ57133316-7E2CD05A-6EFB-465A-87FB-A3F99210A41A
P2860
Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Exploring avidity: understandi ...... nt and heterobivalent ligands.
@en
type
label
Exploring avidity: understandi ...... nt and heterobivalent ligands.
@en
prefLabel
Exploring avidity: understandi ...... nt and heterobivalent ligands.
@en
P2860
P356
P1476
Exploring avidity: understandi ...... nt and heterobivalent ligands.
@en
P2093
Georges Vauquelin
Steven J Charlton
P2860
P304
P356
10.1111/BPH.12106
P407
P577
2013-04-01T00:00:00Z